ReviewMarine drugs2022
Updated Trends on the Biodiscovery of New Marine Natural Products from Invertebrates.
Review in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Unlocking Antimicrobial Peptides from Marine Invertebrates: A Comprehensive Review of Antimicrobial Discovery.Antibiotics (Basel, Switzerland) · 2025Review
- Antibacterial Methyl Ester Cembranoids from the Soft CoralMarine drugs · 2025Article
- Living Coral Displays, Research Laboratories, and Biobanks as Important Reservoirs of Chemodiversity with Potential for Biodiscovery.Marine drugs · 2025Review
- Aquatic Invertebrate Antimicrobial Peptides in the Fight Against Aquaculture Pathogens.Microorganisms · 2025Review
- Nutritional, Antibacterial and Thrombolytic Prospects of FreshwaterFood science & nutrition · 2025Article
- Isolation of Natural Products from Marine Invertebrates.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Antimicrobial, Antioxidant and Anti-Inflammatory Activities of the Mucus of the Tropical Sea SlugMolecules (Basel, Switzerland) · 2024Article
- Diversity and Activity of Bacteria Cultured from a Cup-The SpongeMarine drugs · 2024Article
- Whole genome sequence of the deep-sea sponge Geodia barretti (Metazoa, Porifera, Demospongiae).G3 (Bethesda, Md.) · 2023Article
- Whole genomes of deep-sea sponge-associated bacteria exhibit high novel natural product potential.FEMS microbes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
From 1990-2019, a total of 15,442 New Marine Natural Products from Invertebrates (NMNPIs) were reported. The 2010s saw the most prolific decade of biodiscovery, with 5630 NMNPIs recorded. The phyla that contributed most biomolecules were the Porifera (sponges) (47.2%, 2659 NMNPIs) and the Cnidaria (35.3%, 1989 NMNPIs). The prevalence of these two phyla as the main sources of NMNPIs became more pronounced in the 2010s. The tropical areas of the Pacific Ocean yielded more NMNPIs, most likely due to the remarkable biodiversity of coral reefs. The Indo-Burma biodiversity hotspot (BH) was the most relevant area for the biodiscovery of NMNPIs in the 2010s, accounting for nearly one-third (1819 NMNPIs) of the total and surpassing the top BH from the 1990s and the 2000s (the Sea of Japan and the Caribbean Islands, respectively). The Chinese exclusive economic zone (EEZ) alone contributed nearly one-quarter (24.7%) of all NMNPIs recorded during the 2010s, displacing Japan's leading role from the 1990s and the 2000s. With the biodiscovery of these biomolecules steadily decreasing since 2012, it is uncertain whether this decline has been caused by lower bioprospecting efforts or the potential exhaustion of chemodiversity from traditional marine invertebrate sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.